The highly competitive Bio-Engineering Systems for Therapeutics (BEST) postdoc program, part of the Next-gen Bioengineers initiative, is jointly run by the ETH Zurich and the Roche Pharma Research and Early Development. The program focuses on developing new tools and methods to resolve existing problems and coming up with solutions for future challenges in medical translation and therapeutics.
The Nanophotonic Systems Laboratory (Prof. Romain Quidant, https://light.ethz.ch) at ETH Zurich is searching for a postdoctoral researcher to work on a collaborative project with the Division of ophthalmology at the Roche Pharma Research and Early Development (Roche pRED). The project aims to real-time molecular profile of an organ-on-chip model system for ophthalmologic pathologies by using a newly developed optofluidic platform.
In the Nanophotonic Systems Laboratory (NSL) integrates the latest advances in Photonics with fundamental Physics, Biology, and Engineering to address scientific and technological challenges over a wide spectrum of fields.
Organ-on-chips (OOC) have become a promising approach to developing predictive human models outside the body. One of the unmet goals in OOC development is the lack of real-time monitoring of the model system to capture its maturation, as well as study its response dynamics to stimuli - a critical step for drug discovery, evaluation, and translatability.
The successful candidate will complement our interdisciplinary team,and, in close interaction with our Roche collaborators, apply a newly developed optofluidic platform to real-time molecular profile an OOC model for early diabetic retinopathy. In addition, the candidate will benefit from working at both sites, ETH Zurich, and Roche in Basel.
In close collaboration with multidisciplinary experts you will develop a high throughput molecular profiling assay against disease biomarkers. You will also design and fabricate microfluidic chips on which the molecular fingerprinting assay will run and integrate all these components into a dedicated optofluidic detection platform that enables continuous monitoring. You will then validate the platform against state-of-the-art technologies are essential parts of the project. Finally, you will take the first steps, in collaboration with Roche, to understand the development of disease pathologies from an OOC disease model system. Throughout the project, you will document all activities in an electronic laboratory notebook.
We look forward to receiving your online application with the following documents as a single PDF:
Application deadline: applications can be submitted until December 12, evaluation will be done on a rolling basis.
Please note that we exclusively accept applications submitted through our online application portal. Applications via email or postal services will not be considered.
Further information about [the Nanophotonic Systems Laboratory (NSL) at ETH Zurich] and [the division of ophthalmology at Roche pRED] can be found on the websites: Nanophotonic Systems Laboratory and Ophthalmology.
You can find more information about the Next-gen Bioengineers doctoral programme on the website: Next-gen Bioengineers. In case of any administrative issues, please contact the Programme office by email [firstname.lastname@example.org].
Biomarker lipids for past environmental change - PhD positionThe Earth Ecosystem Dynamics Group (Geological Institute, Department of Earth Sciences) at ETH Zurich is looking for a highly motivated ...
PhD Position: Nanotechnology for Chemical Sensors in Medical DiagnosticsThe Human-centered Sensing Laboratory (HSL) at ETH Zürich is looking for a doctoral student to perform fundamental and applie...
PhD position: Trace element cycling at the oxic-anoxic interface of redox-stratified lakesThroughout most of Earth’s history, aquatic environments were characterized by limited availability of oxyg...
PhD position: Robot-assisted eDNA collection methods for biodiversity monitoringThe Ecosystems and Landscape Evolution group, the Environmental Robotics Lab, and the Environmental DNA group at ETH ...